Therapeutic Solutions International, INC

Therapeutic Solutions International, Inc. announces its intention to voluntarily withdraw its common stock from listing and registration on the OTC Markets.

Therapeutic Solutions International (TSOI) is offering a one-time loyalty dividend to its shareholders in the form of Breathe Biologics (BRTH) shares.

Therapeutic Solutions International (TSOI) will issue a one-time loyalty dividend of Breathe Biologics (BRTH) shares to TSOI shareholders.

Therapeutic Solutions International has increased its authorized share count from 6.5 billion to 9 billion common shares and authorized 5 million preferred shares after receiving shareholder approval.

Therapeutic Solutions International has initiated a civil action against the University of Miami and others in the Southern District of California.

Therapeutic Solutions International has extended the deadline for shareholders to elect to receive a loyalty dividend in the form of Campbell Neurosciences, Inc. shares to September 30, 2024.

Therapeutic Solutions International reported a net loss of $3.26 million for the nine months ended September 30, 2024, driven by increased consulting and legal fees, despite a decrease in research and development expenses.

Therapeutic Solutions International reported a net loss for the second quarter of 2024, alongside a decrease in revenue, while continuing to advance its research and development programs.

Therapeutic Solutions International reported a net loss of $585,141 for the first quarter of 2024, highlighting ongoing financial challenges and the need for additional capital.

Therapeutic Solutions International reports a net loss of $2.2 million for 2023, highlighting ongoing financial challenges and the need for additional capital.

CEO Timothy Dixon reports acquiring and disposing of shares in Therapeutic Solutions International, Inc.

Director Thomas Ichim reports acquisition and disposal of Therapeutic Solutions International (TSOI) common stock.

Timothy G. Dixon, President & CEO of Therapeutic Solutions International, acquires 13,333,333 shares of common stock at $0.0006 per share.

Thomas Ichim, a director of Therapeutic Solutions International, acquired 10,000,000 shares of common stock at a price of $0.0006 per share on July 11, 2024.

Timothy G. Dixon, President & CEO of Therapeutic Solutions International, acquires 20,000,000 shares of common stock at $0.0006 per share.

Thomas Ichim, a director of Therapeutic Solutions International, acquired 10 million shares of common stock at $0.0008 per share and disposed of 187 million shares on July 8, 2024.

Therapeutic Solutions International amends its S-1 registration statement to facilitate the sale of up to 300 million shares of common stock by a selling shareholder, potentially raising $9.2 million for working capital.

Therapeutic Solutions International (TSOI) has filed a prospectus for the resale of up to 300 million shares of its common stock by a selling shareholder, with the company potentially receiving up to $9.2 million from initial sales to GHS Investments, LLC.